All In Biotech

Drug Trial Radar · NCT06660342

A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring

Vonoprazan Pregnancy Registry: An Observational Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

728

Planned (sponsor's estimate)

Start

May 15, 2025

Primary completion

Sep 2034

Study completion Sep 2034

Sponsor

Lead sponsor
Phathom Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Oct 28, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
Female only, from 15 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of the study is to compare the maternal, fetal, and infant outcomes of pregnant women who are exposed to vonoprazan during pregnancy with outcomes of an internal comparison cohort of pregnant women who are unexposed to vonoprazan during pregnancy but who may be exposed to other products for the treatment of conditions for which vonoprazan may be prescribed.

Conditions

  • Erosive Esophagitis
  • Heartburn
  • Symptomatic Non-erosive Gastroesophageal Reflux Disease
  • Helicobacter Pylori Infection

Interventions

  • VonoprazanDrug

    Oral tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Major Congenital Malformations (MCMs)Time frame: Date of conception (DOC) to pregnancy outcome for fetal losses (approximately 40 gestational weeks) or 12 months from birth for live births

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PPD

    Wilmington, North Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.